Stuttgart
06.02.26 | 21:55
18,600 Euro
0,00 % 0,000
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 18,600 | 19,120 | 13:05 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 27.01. | XVIVO Perfusion AB: Year-End Report 2025 | 243 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / January 27, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV)Fourth quarter 2025 (Oct-Dec)Net sales amounted to SEK 226.1 million (227.6), corresponding to... ► Artikel lesen | |
| 15.01. | XVIVO Perfusion AB: Conference Call on Year-End Report 2025 | 234 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / January 15, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - Invitation to attend XVIVO's conference call regarding the presentation of the Year-end Report... ► Artikel lesen | |
| XVIVO PERFUSION Aktie jetzt für 0€ handeln | |||||
| 06.01. | XVIVO Perfusion AB: XVIVO's CEO to present at J.P. Morgan's 44th Annual Healthcare Conference in San Francisco | 213 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / January 6, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - Today, XVIVO announced its participation in the 44th annual J.P. Morgan Healthcare Conference... ► Artikel lesen | |
| 23.10.25 | XVIVO Perfusion AB: Interim Report January-September 2025 | 280 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / October 23, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV)Third quarter 2025 (Jul-Sep)Net sales amounted to SEK 189.1 million (198.5), corresponding to growth... ► Artikel lesen | |
| 13.10.25 | XVIVO Perfusion AB: Conference Call on Interim Report July-September 2025 | 352 | ACCESS Newswire | GOTHENBURG, SWEDEN / ACCESS Newswire / October 13, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - Invitation to attend XVIVO's conference call regarding the interim report July-September... ► Artikel lesen | |
| 05.09.25 | Nomination Committee of XVIVO Perfusion AB | 284 | ACCESS Newswire | GOTHENBURG, SWEDEN / ACCESS Newswire / September 5, 2025 / The following members have been appointed to XVIVO Perfusion's (STO:XVIVO)(LSE:0RKL)(FRA:3XV) nomination committee for the 2026 annual general... ► Artikel lesen | |
| 28.07.25 | XVIVO Perfusion AB: Delay in CE Approval for XVIVO's Perfusion Solution for Heart Preservation | 644 | ACCESS Newswire | GOTHENBURG, SWEDEN / ACCESS Newswire / July 28, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV). The XVIVO Heart Assist Transport and the XVIVO Heart Assist Transport Perfusion Set have received... ► Artikel lesen | |
| 21.07.25 | XVIVO Perfusion AB: First Patient Enrolled in US PRESERVE CAP Study for XVIVO Heart Assist Transport Device | 362 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / July 21, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - Today, XVIVO announces that the first patient has been enrolled as part of the Continued Access... ► Artikel lesen | |
| 11.07.25 | XVIVO Perfusion AB: Interim Report January-June 2025 | 429 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / July 11, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV)A quarter showing a mixed pictureSecond quarter 2025 (Apr-Jun)• Net sales amounted to SEK 178.3 million... ► Artikel lesen | |
| 10.07.25 | XVIVO Perfusion AB: Conference Call on Interim Report April-June 2025 | 423 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / July 10, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - Invitation to attend XVIVO's conference call regarding the interim report April-June 2025. The... ► Artikel lesen | |
| 13.06.25 | XVIVO Perfusion AB: XVIVO Honored with 2025 SACC-USA Business Award for Life-Saving Innovation and Growth in the U.S. Market | 369 | ACCESS Newswire | GOTHENBURG, SWEDEN / ACCESS Newswire / June 13, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - Yesterday, XVIVO received the prestigious Swedish American Chamber of Commerce USA (SACC-USA)... ► Artikel lesen | |
| 29.04.25 | XVIVO Perfusion AB: XVIVO Presents 12-Month Follow-Up Results from European Multicenter Heart Transplantation Trial at ISHLT in Boston | 384 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / April 29, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - The 12-month follow-up results from XVIVO's European multicenter heart trial, NIHP2019, was presented... ► Artikel lesen | |
| 25.04.25 | Bulletin from Annual General Meeting in XVIVO Perfusion AB | 479 | ACCESS Newswire | GOTHENBURG, SWEDEN / ACCESS Newswire / April 25, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV)The following resolutions were passed at the Annual General Meeting (the "AGM") of XVIVO Perfusion... ► Artikel lesen | |
| 24.04.25 | XVIVO Perfusion AB: Interim Report January-March 2025 | 356 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / April 24, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV)First quarter 2025 (Jan-Mar)Net sales increased to SEK 218.6 million (186.0), corresponding to growth... ► Artikel lesen | |
| 15.04.25 | XVIVO Perfusion AB: Conference Call on Interim Report January-March 2025 | 460 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / April 15, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - Invitation to attend XVIVO's conference call regarding the interim report January-March 2025.... ► Artikel lesen | |
| 02.04.25 | XVIVO Perfusion AB: Annual Report 2024 | 520 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / April 2, 2025 / XVIVO Perfusion AB (STO:XVIVO) (LSE:0RKL) (FRA:3XV)Today XVIVO Perfusion AB (publ) publish the Annual Report for 2024. The Annual Report is attached... ► Artikel lesen | |
| 20.03.25 | Notice to Attend the Annual General Meeting in XVIVO Perfusion AB | 436 | ACCESS Newswire | GOTHENBURG, SWEDEN / ACCESS Newswire / March 20, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) (publ) (the "Company"), reg. no. 556561-0424, with its registered office in Mölndal, gives notice... ► Artikel lesen |
17 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ECKERT & ZIEGLER | 15,440 | +1,65 % | BERENBERG stuft ECKERT & ZIEGLER auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat die Einstufung für Eckert & Ziegler mit einem Kursziel von 24 Euro auf "Buy" belassen. Die vorläufigen Zahlen für 2025 hätten beim Umsatz und... ► Artikel lesen | |
| UNITEDHEALTH | 232,15 | -0,77 % | UnitedHealth: Das sieht gar nicht gut aus | Der enttäuschende Ausblick, den UnitedHealth dem Kapitalmarkt vor Kurzem an die Hand gegeben hat, und maue Aussichten für 2027 hinterlassen weitere Spuren im Aktienkurs des größten US-Krankenversicherers.... ► Artikel lesen | |
| INTUITIVE SURGICAL | 413,35 | +0,02 % | INTUITIVE SURGICAL INC - 10-K, Annual Report | ||
| RHOEN-KLINIKUM | 13,200 | +1,54 % | EQS-Adhoc: RHÖN-KLINIKUM Aktiengesellschaft: RHÖN-KLINIKUM passt die EBITDA-Prognose für das Geschäftsjahr 2025 an | EQS-Ad-hoc: RHÖN-KLINIKUM Aktiengesellschaft / Schlagwort(e): Prognoseänderung
RHÖN-KLINIKUM Aktiengesellschaft passt die EBITDA-Prognose für das Geschäftsjahr 2025 an... ► Artikel lesen | |
| HIMS & HERS HEALTH | 19,500 | +0,15 % | BREAKING: Hims & Hers verschärft Preisdruck bei Novo Nordisk - Aktie beschleunigt Talfahrt | Der dänische Biopharma-Riese ist erst seit wenigen Wochen mit seinem Appetitzügler Wegovy als Tablette auf dem US-Markt und sieht sich einem massiven Preisdruck ausgesetzt. Das Telehealth-Unternehmen... ► Artikel lesen | |
| BICO GROUP | 1,594 | -0,25 % | BICO Group AB: BICO company Biosero launches GoSimple, a standardized automation-ready workcell with selected instruments from Sartorius and Becton, Dickinson and Company (BD) | Biosero, part of the BICO Group and a leader in lab automation, will launch the GoSimple workcell at SLAS 2026 (February 7-11, Boston, US). GoSimple is a standardized, automation-ready workcell designed... ► Artikel lesen | |
| M1 KLINIKEN | 17,100 | +3,01 % | M1 Kliniken schließt Verkauf von Haemato Pharm ab | Die M1 Kliniken AG hat den Verkauf der Haemato Pharm GmbH über ihre Mehrheitsbeteiligung Haemato AG an die Phoenix Group mit Wirkung zum Ablauf des 31. Januar 2026 abgeschlossen. Sämtliche Vollzugsbedingungen... ► Artikel lesen | |
| BAXTER | 18,232 | -0,83 % | Is Baxter International an Underrated Healthcare Investment Play? | ||
| ASENSUS SURGICAL | - | - | GlobalLogic, Asensus ink surgical robotics engineering collab | ||
| JD HEALTH INTERNATIONAL | 6,350 | -3,05 % | CLSA Keeps Rating at Outperform for JD HEALTH , Raises Earnings Forecasts | ||
| LIFEWARD | 0,570 | +5,01 % | Oramed Pharmaceuticals Inc.: Oramed and Lifeward Announce Strategic Transaction | Transaction Will Transfer Oramed's Oral Drug Delivery Platform (POD Technology) to Lifeward and Positions Oramed as a Significant Shareholder
Oramed will transfer... ► Artikel lesen | |
| COOPER COMPANIES | 68,50 | -1,44 % | CooperCompanies Announces Release Date for First Quarter 2026 | ||
| SURGICAL SCIENCE SWEDEN | 2,302 | -0,86 % | Surgical Science Sweden AB: Surgical Science announces new financial targets and initiates the process of a listing transfer | Surgical Science today communicates new financial targets. Growth shall amount to 10-15% annually with an adjusted EBIT of at least 15%. The company estimates that the targets will be met in 2027. As... ► Artikel lesen | |
| ONWARD MEDICAL | 4,190 | -0,95 % | ONWARD Medical NV: ONWARD Medical Announces First Participant Enrolled in Global Pivotal Study Evaluating ARC-IM System to Address Blood Pressure Instability After Spinal Cord Injury | Empower BP is a landmark global pivotal study evaluating the safety and effectiveness
of the implantable ARC-IM System
to address blood pressure instability after spinal cord injury (SCI)Blood... ► Artikel lesen | |
| PERSPECTIVE THERAPEUTICS | 4,000 | +1,52 % | Perspective Therapeutics Prices Approx. $175 Mln Offering Of Shares And Pre-Funded Warrants |
Das Unternehmen XVIVO PERFUSION AB kann der Branche Gesundheitswesen zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 18,600 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu XVIVO PERFUSION AB finden Sie auf Wallstreet Online.